Shijiazhuang No. 4 Pharmaceutical: 95 Products Included in China’s National Essential Medicines List (2026 Edition)

Shijiazhuang No. 4 Pharmaceutical Group said 95 of its product varieties have been included in China’s National Essential Medicines List (2026 Edition).

According to Jin10, the company disclosed in a filing to the Hong Kong Stock Exchange that the 95 included varieties contain 32 newly added varieties.

The newly added varieties listed by the company are: glucose and sodium chloride injection; levofloxacin lactate and sodium chloride injection; levofloxacin and sodium chloride injection; sodium bicarbonate injection; fluconazole tablets; gliclazide tablets; Qingre Jiedu oral liquid; potassium chloride injection; mecobalamin injection; ambroxol hydrochloride injection; bromhexine hydrochloride injection; medium- and long-chain fat emulsion injection; azithromycin for injection; acetaminophen tablets; azithromycin dry suspension; ipratropium bromide inhalation solution; lurasidone hydrochloride tablets; urapidil hydrochloride injection; citicoline sodium injection; oseltamivir phosphate dry suspension; aminophylline injection; magnesium sulfate injection; cefuroxime axetil dry suspension; ondansetron hydrochloride injection; entacapone tablets; isosorbide dinitrate injection; betahistine mesylate tablets; norepinephrine bitartrate injection; levamlodipine besylate tablets; levofloxacin eye drops; propafenone hydrochloride injection; and metoclopramide hydrochloride injection.

The company said the list will be implemented starting September 1, 2026, and it expected the inclusion to have a positive impact on the group’s growth and business development.